Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

Biotech IPOs Infographic

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Tekmira CEO Discusses Ebola Therapy Development at 2014 BIO Investor Forum

Tekmira CEO

Today at the 13th Annual BIO Investor Forum, Tekmira CEO Dr. Mark Murray participated in a conversation with Phyllis Arthur, BIO’s Senior Director for Vaccines, Immunotherapeutics, and Diagnostics Policy. Tekmira has been in the spotlight recently due to their experimental Ebola therapy, TKM-Ebola. Recently, they announced that FDA has allowed them to provide TKM-Ebola for treatment under expanded access protocols, and that they have joined an international consortium to conduct clinical trials of Ebola virus therapeutics Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO 2015 – Call for Sessions Extended

115x76-cfs

It’s not too late to submit a session proposal for the 2015 BIO International Convention. We’ve just extended the submission deadline until Wednesday, October 8th at 5:00 pm EDT. All ideas are welcome! We seek proposals that reflect current trends and novel ideas in all focus areas Business Development & Finance Biomedical Technology: Research & Development Digital Health General Biotechnology Interest Intellectual Property Value, Market Access & Commercialization View the full list here. If you’d Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What to Watch: Vaccines – Calling the Shots

vaccines-calling-shots-vi

Recently, PBS’s NOVA had an episode on the reemergence of diseases (including measles, whooping cough, and mumps) that had previously been largely eradicated in the US by vaccines, in part because nervous parents are skipping their children’s shots. At least ten percent of parents delay or skip some recommended vaccines, and one percent don’t vaccinate at all. What’s driving people away, and what are the consequences? Those are the questions explored in Vaccines — Calling Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,